| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15150316 | IVR | 40 mg/kg | 40 mg/kg | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:16440597 | IVR | 0.1 mg/kg | 0.1 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:16786173 | IVR | 0.003 mmol/kg | 0.003 mmol/kg | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations |
| IVR | 0.003 mmol/kg | 0.003 mmol/kg | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| PMID:21453761 | IVR | 0.8 mg/kg | 0.8 mg/kg | Increased levels of norepinephrine | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Increased levels of norepinephrine | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased levels of norepinephrine | Neurological endocrine-mediated perturbations | |
| PMID:21933864 | IVR | 1 mg/kg | 1 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decreased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased oxytocin levels | Reproductive endocrine-mediated perturbations | |
| PMID:27220267 | IVR | 0.2 mg/kg | 0.2 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased levels of norepinephrine | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased levels of epinephrine | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increased dopamine levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg | 0.2 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:30175909 | IVR | 10 mg/kg | 10 mg/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 7 mg/kg | 7 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 12 mg/kg | 12 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| PMID:6223748 | IVR | 0.01 mg/day | 0.01 mg/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 0.005 mg/day | 0.005 mg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/day | 0.005 mg/day | Atrophy in lymphoid tissues | Immunological endocrine-mediated perturbations | |
| IVR | 0.005 mg/day | 0.005 mg/day | Atrophy of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.005 mg/day | 0.005 mg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.005 mg/day | 0.005 mg/day | Changes in T-cell populations | Immunological endocrine-mediated perturbations | |
| IVR | 0.005 mg/day | 0.005 mg/day | Atrophy of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Atrophy in lymphoid tissues | Immunological endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Atrophy of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Atrophy of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.0025 mg/day | 0.0025 mg/day | Changes in T-cell populations | Immunological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.